Posted inGastroenterology Infectious Diseases news
High Efficacy and Tolerability of an 8-Week Bemnifosbuvir and Ruzasvir Regimen in Chronic Hepatitis C: Insights from a Phase 2 Study
An 8-week course of bemnifosbuvir and ruzasvir showed high sustained virologic response rates with excellent safety in treatment-naïve chronic hepatitis C patients across genotypes, including those with baseline resistance mutations.